Image

    Tofacitinib as a Pragmatic Treatment Choice for Alopecia Areata: A Retrospective Review

    January 2022 in “ Dermatologic Therapy ”
    Sarah Benton, Ronda S. Farah, Rebecca Freese, Maria Hordinsky
    Studysummary In this retrospective analysis, the authors reported that off-label tofacitinib treatment in 35 alopecia areata patients demonstrated safety, with no serious adverse events, and effectiveness, with 83.9% showing significant scalp regrowth and 32.3% achieving near total or total regrowth.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on onlinelibrary.wiley.com →
    Discuss this study in the Community →

    Research cited in this study 20

    1. Low-Dose Tofacitinib for Treating Patients with Severe Alopecia Areata: An Efficient and Cost-Saving Regimen European Journal of Dermatology · 2019
    2. Benefit and Risk Profile of Tofacitinib for the Treatment of Alopecia Areata: A Systematic Review and Meta-Analysis Journal of the European Academy of Dermatology and Venereology · 2019
    3. Treatment of Alopecia Universalis with Topical Janus Kinase Inhibitors – A Double Blind, Placebo, and Active Controlled Pilot Study International Journal of Dermatology · 2018
    4. Topical 2% Tofacitinib for Children with Alopecia Areata, Alopecia Totalis, and Alopecia Universalis Journal of the American Academy of Dermatology · 2018
    5. Alopecia Areata: Overview and Insights from January 2018 Journal of The American Academy of Dermatology · 2017
    6. Tofacitinib 2% Ointment, a Topical Janus Kinase Inhibitor, for the Treatment of Alopecia Areata: A Pilot Study of 10 Patients Journal of the American Academy of Dermatology · 2017
    7. Oral Tofacitinib Monotherapy in Korean Patients with Refractory Moderate-to-Severe Alopecia Areata: A Case Series Journal of the American Academy of Dermatology · 2017
    8. Complete Regrowth of Beard Hair with Ruxolitinib in an Alopecia Universalis Patient Skin appendage disorders · 2017
    9. Treatment of Severe Alopecia Areata with Oral Tofacitinib: A Case Series Journal of the American Academy of Dermatology · 2017
    10. Treatment of Alopecia Areata With Tofacitinib JAMA Dermatology · 2017
    11. Tofacitinib for the Treatment of Alopecia Areata and Variants in Adolescents Journal of the American Academy of Dermatology · 2016
    12. Tofacitinib for the Treatment of Severe Alopecia Areata and Variants: A Study of 90 Patients Journal of The American Academy of Dermatology · 2016
    13. Safety and Efficacy of the JAK Inhibitor Tofacitinib Citrate in Patients with Alopecia Areata JCI insight · 2016
    14. Oral Ruxolitinib Induces Hair Regrowth in Patients with Moderate-to-Severe Alopecia Areata JCI insight · 2016
    15. Topical Ruxolitinib for the Treatment of Alopecia Universalis JAMA dermatology · 2015
    16. Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib EBioMedicine · 2015
    17. Inhibiting Janus Kinases to Treat Alopecia Areata Nature medicine · 2014
    18. Alopecia Areata Is Driven by Cytotoxic T Lymphocytes and Is Reversed by JAK Inhibition Nature medicine · 2014
    19. Alopecia Areata: An Autoimmune Disease Causing Hair Loss The New England Journal of Medicine · 2012
    20. Genome-Wide Association Study in Alopecia Areata Implicates Both Innate and Adaptive Immunity Nature · 2010

    Related research 1

    1. Successful Treatment of Severe Alopecia Areata With Oral or Topical Tofacitinib PubMed · 2018